The Board of Directors has with immediate effect among its members elected Maria Rankka to serve as Board Chair of BICO Group AB, until a new chair has been elected by the shareholders' meeting. Maria Rankka succeeds Rolf Classon who, for health reasons, has chosen to resign from his position on the board and as Board Chair.
"It is with warm regards and confidence that I hand over to Maria Rankka. The Board's election guarantees focus on the strategy, BICO 2.0, and to deliver on the work of further advancing the company's position both from a commercial and communicative standpoint. I would like to thank my fellow board members, the executive management, and shareholders for your trust and cooperation during my time as Board Chair", says Rolf Classon, former Board Chair of BICO Group AB.
Maria Rankka (born 1975) was elected board member at the Annual General Meeting in May this year. Maria Rankka is an investor and entrepreneur, mainly in Health Tech and Life Science. She is also Board Chair of the Swedish stem cells company Cellcolabs and was one of the co-founders of ABC Labs, which was Sweden's largest covid laboratory during the pandemic. Maria was previously partner at Brunswick and was the CEO of the Stockholm Chamber of Commerce, 2010-2018. Maria has experience from board work in several listed companies in various industries. She is a board member of Creades and Genova, among others.
"BICO has an important mission in supporting pharma companies, biopharma, and academia in bringing innovations to market more quickly - innovations that contribute to healthier societies. During the pandemic, I personally experienced the power of automating laboratories through both hardware and software. I look forward to increasing my engagement and actively contributing to the company's onward journey in my new role", says Maria Rankka, Board Chair of BICO Group AB.
For further information, please contact:
Maria Rankka, Board Chair, BICO Group AB
Phone: +46 (0) 702-10 11 44
E-mail: ir@bico.com
This information is information that BICO Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-09-16 18:28 CEST.
About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 10,900 publications. Operating through two business areas - Lab Automation and Life Science Solutions - BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
